

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

Data Sheet (Cat.No.T1272)



Cytarabine

Chemical Proper	ties
CAS No. :	147-94-4
Formula:	C9H13N3O5
Molecular Weight:	243.22
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year

Biological Description

Description	Cytarabine (Ara-C) is a nucleoside analog, an inhibitor of DNA synthesis (IC50=16 nM). Cytarabine inhibits DNA polymerase and induces cell cycle arrest, autophagy, and apoptosis. Cytarabine has antitumor activity.
Targets(IC50)	Apoptosis,Nucleoside Antimetabolite/Analog,DNA/RNA Synthesis,Endogenous Metabolite,Autophagy,HSV
In vitro	 METHODS: Primary AML cells were treated with Cytarabine (10-5000 nM) for 24 h. Cell viability was measured using MTT method. RESULTS: Cytarabine showed a dose-dependent growth inhibitory effect with an IC50 of 1.12 μM. [1] METHODS: Human histiocytic lymphoma cells U937 were treated with Cytarabine (10-1000 nM) for 72 h, and the cell cycle was detected by Flow Cytometry. RESULTS: Cytarabine dose-dependently decreased the proportion of cells in G1 phase and increased the proportion of cells in S phase in cells treated with 10 and 100 nM. At the highest dose of 1000 nM, Cytarabine caused a significant increase in the proportion of sub-G1 and G2/M phases. [2]
	Translated with DeepL.com (free version)
In vivo	 METHODS: To study chemotherapy resistance in AML, Cytarabine (10-60 mg/kg) was administered intraperitoneally to NSG mice bearing human AML tumors once daily for five days. RESULTS: In all mice treated with 60 mg/kg Cytarabine, cytoreduction occurred at 2 weeks post-treatment and relapsed 4-13 weeks post-treatment. There was a dose-response relationship in the model in terms of minimum leukemia burden and time to peripheral blood relapse. [3] METHODS: To assay antitumor activity in vivo, Cytarabine (6.25 mg/kg once daily) and sorafenib (60 mg/kg twice daily) were administered intraperitoneally to a NOD-SCID-IL2R γnull mouse model harboring the human AML tumor U937 once weekly or for forty-eight days. RESULTS: Cytarabine in combination with sorafenib produced potent anti-AML activity in vivo. [4]
	Translated with DeepL.com (free version)
Kinase Assay	In Vitro Growth Inhibition Assay: Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended

24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4- hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell		in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continu- for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of th control value).	
	Cell Research	Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4- hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay(Only for	

Solubility Information

Solubility	DMSO: 55 mg/mL (226.13 mM),	
	H2O: 24.3 mg/mL (100 mM),	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1115 mL	20.5575 mL	41.115 mL
5 mM	0.8223 mL	4.1115 mL	8.223 mL
10 mM	0.4112 mL	2.0558 mL	4.1115 mL
50 mM	0.0822 mL	0.4112 mL	0.8223 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

He S, Li Y, Shi X, et al.DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t (8; 21) acute myeloid leukemia.Clinical Epigenetics.2023, 15(1): 1-13.

Inhibitor • Natural Compounds • Compound Libraries • Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481